NKTR - CIK 0000906709
NEKTAR THERAPEUTICS trades as NKTR and has a market capitalization of $1.93 B, making it the #2118 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $55.23M, down 43.9% from the prior year and net income of -$164.00M. This page tracks NEKTAR THERAPEUTICS through 1,949 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years NEKTAR THERAPEUTICS's revenue declined from $165.44M to $55.23M, a compound annual decline rate of 11.5%. Net profit margin compressed from -92.8% to -296.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| New insider ownership | 3 | 2026-05-26 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Prospectus supplement | 424B5 | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York | Nektar Therapeutics
Nektar Therapeutics Reports First Quarter 2026 Financial Results | Nektar Therapeutics
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Nektar Therapeutics
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 7, 2026.
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | Nektar Therapeutics
The largest companies sharing NEKTAR THERAPEUTICS's SEC industry classification (pharmaceutical preparations).
NEKTAR THERAPEUTICS (NKTR) has a market capitalization of $1.93 B as of 2026-06-10, ranking #2118 among US-listed companies.
NEKTAR THERAPEUTICS reported revenue of $55.23M for fiscal year 2025, a decrease of 43.9% year over year.
In its latest fiscal year NEKTAR THERAPEUTICS reported a net loss of $164.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.